Cost-effectiveness Analysis of Atezolizumab Plus Nab-Paclitaxel for Advanced PD-L1 Positive Triple-Negative Breast Cancer in Japan

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

Roy S. Herbst, Jean‐Charles Soria, Marcin Kowanetz et al. · Nature · 2014 · 5.3K citations

Medicine, Immunology, Oncology +16

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

Peter Schmid, Sylvia Adams, Hope S. Rugo et al. · New England Journal of Medicine · 2018 · 4.4K citations · Full text

Medicine, Oncology, Pharmacology +17

Markov Models in Medical Decision Making

Frank A. Sonnenberg, J. Robert Beck · Medical Decision Making · 1993 · 2.4K citations

Business, Decision Sciences, Clinical Decision Support +16

Updating Cost-Effectiveness — The Curious Resilience of the $50,000-per-QALY Threshold

Peter J. Neumann, Joshua T. Cohen, Milton C. Weinstein · New England Journal of Medicine · 2014 · 2.3K citations

Pharmacy, Health Policy, Pharmacoeconomics +17

3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

Fátima Cardoso, A. Costa, Elżbieta Senkus et al. · Annals of Oncology · 2016 · 2.1K citations · Full text

Medicine, Oncology, Breast Oncology +11